Tomasello Shawn

SEC source: 0001193125-26-276168 · ownership.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-06-16

F1 · kind: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

SEC source: 0001193125-26-266239 · ownership.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2036-06-08

F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Corporation's stockholders.

SEC source: 0001193125-26-018324 · ownership.xml · nonDerivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Shawn Tomasello Consulting LLC

Disclosed balance after: 22,725

SEC source: 0000950170-25-088489 · ownership.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2035-06-16

F1 · kind: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

SEC source: 0000950170-25-084015 · ownership.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2035-06-08

F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 9, 2026 or (ii) the date of the next annual meeting of the Corporation's stockholders.

SEC source: 0000950170-25-074823 · ownership.xml · derivative · entry 4

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2034-06-02

F3 · derivative.exercise_price: The exercise price of the option is $1.92 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period", through which the Reporting Person must remain in service to the Issuer, commenced on the Repricing Date and ends upon the earliest of (i) the one-year anniversary of the Repricing Date, (ii) a Sale Event (as defined in the 2018 Plan and 2019 Plan, as applicable) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2018 Plan and 2019 Plan, as applicable) due to the Reporting Person's death or disability.

F1 · kind: On May 15, 2025, the Issuer's board of directors approved an option repricing (the "Repricing"), to be effective May 19, 2025 (the "Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan, as amended (the "2018 Plan") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, as amended (the "2019 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-074823 · ownership.xml · derivative · entry 3

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,000 shares

Expires 2034-06-02

F1 · kind: On May 15, 2025, the Issuer's board of directors approved an option repricing (the "Repricing"), to be effective May 19, 2025 (the "Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan, as amended (the "2018 Plan") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, as amended (the "2019 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-074823 · ownership.xml · derivative · entry 2

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2033-07-20

F3 · derivative.exercise_price: The exercise price of the option is $1.92 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period", through which the Reporting Person must remain in service to the Issuer, commenced on the Repricing Date and ends upon the earliest of (i) the one-year anniversary of the Repricing Date, (ii) a Sale Event (as defined in the 2018 Plan and 2019 Plan, as applicable) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2018 Plan and 2019 Plan, as applicable) due to the Reporting Person's death or disability.

F1 · kind: On May 15, 2025, the Issuer's board of directors approved an option repricing (the "Repricing"), to be effective May 19, 2025 (the "Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan, as amended (the "2018 Plan") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, as amended (the "2019 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-074823 · ownership.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 44,000 shares

Expires 2033-07-20

F1 · kind: On May 15, 2025, the Issuer's board of directors approved an option repricing (the "Repricing"), to be effective May 19, 2025 (the "Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan, as amended (the "2018 Plan") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, as amended (the "2019 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-24-070596 · ownership.xml · nonDerivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

SEC source: 0000950170-24-068982 · ownership.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2034-06-02

F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 3, 2025 or (ii) the date of the next annual meeting of the Corporation's stockholders.

SEC source: 0000950170-24-064259 · ownership.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2034-05-20

F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 21, 2025 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 21, 2027. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

SEC source: 0001415889-24-002335 · form4-02022024_090240.xml · nonDerivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 241,977

F1 · shares: Represents a restricted share unit award, which shall vest on January 31, 2025, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001209191-23-053267 · doc4a.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Ordinary Shares · 17,000 shares

Expires 2023-10-18

F1 · date: The option grant was approved by the Board of Directors of the Issuer on March 20, 2023, subject to shareholder approval. The Issuer's shareholders approved the grant at the annual general meeting of the shareholders on October 19, 2023.

F2 · derivative.exercise_date: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001209191-23-053265 · doc4a.xml · derivative · entry 2

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,600

Underlying: Ordinary Shares · 56,600 shares

Expires 2033-10-18

F3 · date: The option grant was approved by the Board of Directors of the Issuer on February 8, 2023, subject to shareholder approval. The Issuer's shareholders approved the grant at the annual general meeting of the shareholders on October 19, 2023.

F4 · derivative.exercise_date: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001209191-23-053265 · doc4a.xml · nonDerivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,977

F1 · date: The restricted stock unit ("RSU") award was approved by the Board of Directors of the Issuer on February 8, 2023, subject to shareholder approval. The Issuer's shareholders approved the award at the annual general meeting of the shareholders on October 19, 2023.

F2 · shares: Represents an RSU award, which shall vest on February 8, 2024, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0000950170-23-033944 · ownership.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2033-07-20

F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in twelve substantially equal quarterly installments following July 21, 2023, subject to the reporting person's continued service on each such vesting date.

SEC source: 0001104659-23-067078 · tm2317472-11_4seq1.xml · derivative · entry 4

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,177 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F2 · kind: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F2 · derivative.exercise_date: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F2 · derivative.expiration_date: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

SEC source: 0001104659-23-067078 · tm2317472-11_4seq1.xml · derivative · entry 3

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,191 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F2 · kind: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F2 · derivative.exercise_date: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F2 · derivative.expiration_date: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

SEC source: 0001104659-23-067078 · tm2317472-11_4seq1.xml · derivative · entry 2

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,100 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F2 · kind: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F2 · derivative.exercise_date: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F2 · derivative.expiration_date: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

SEC source: 0001104659-23-067078 · tm2317472-11_4seq1.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,800 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F2 · kind: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F2 · derivative.exercise_date: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F2 · derivative.expiration_date: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

SEC source: 0001610717-23-000072 · form4.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2033-05-22

F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2024 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2026. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

SEC source: 0001209191-23-029097 · doc4.xml · nonDerivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) May 11, 2024 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0001209191-23-020521 · doc4.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Ordinary Shares · 17,000 shares

Expires 2033-03-19

F1 · derivative.exercise_date: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001209191-23-008551 · doc4.xml · derivative · entry 2

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,600

Underlying: Ordinary Shares · 56,600 shares

Expires 2033-02-07

F2 · derivative.exercise_date: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001209191-23-008551 · doc4.xml · nonDerivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,977

F1 · shares: Represents a restricted share unit award, which shall vest on February 8, 2024, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0000899243-22-039011 · doc4.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,800

Underlying: Common Stock · 16,800 shares

Expires 2032-12-14

F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter.

SEC source: 0001209191-22-058395 · doc4.xml · derivative · entry 2

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,500

Underlying: Ordinary Shares · 9,500 shares

Expires 2032-11-17

F2 · derivative.exercise_date: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on February 1, 2023, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001209191-22-058395 · doc4.xml · nonDerivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,677

F1 · shares: Represents a restricted share unit award, which shall vest on November 1, 2023, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001209191-22-052284 · doc4.xml · nonDerivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,677

F1 · price: The reporting person purchased ordinary shares of the Issuer at a price of $1.55 per share in an underwritten public offering by the Issuer, which closed on September 30, 2022.

SEC source: 0001567619-22-011723 · doc1.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2032-05-22

F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2023 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2025. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

SEC source: 0000899243-22-018805 · doc4.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,500

Underlying: Common Stock · 27,500 shares

Expires 2032-05-16

F1 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) May 17, 2023 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-22-012968 · doc4.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2032-03-29

F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in twelve (12) equal quarterly installments, with the first installment vesting on June 29, 2022.

SEC source: 0001209191-21-069058 · doc4.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,100

Underlying: Common Stock · 12,100 shares

Expires 2031-12-08

F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in twenty-four (24) equal monthly installments thereafter.

SEC source: 0001209191-21-039133 · doc4.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-06

F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year.

SEC source: 0001567619-21-010746 · doc1.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2031-05-16

F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 17, 2022 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 17, 2024. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

SEC source: 0001209191-21-007718 · doc4.xml · derivative · entry 2

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,177

Underlying: Common Stock · 4,177 shares

Expires 2031-02-02

F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 3, 2022, with the remainder vesting in twenty-four (24) equal monthly installments thereafter

SEC source: 0001209191-21-007718 · doc4.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,191

Underlying: Common Stock · 15,191 shares

Expires 2031-02-02

F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 3, 2022, with the remainder vesting in twenty-four (24) equal monthly installments thereafter

SEC source: 0001209191-20-052237 · doc4.xml · derivative · entry 2

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,240 shares

Expires 2030-06-03

F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.

SEC source: 0001209191-20-052237 · doc4.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,475 shares

Expires 2029-08-28

F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.

SEC source: 0001209191-20-035684 · doc4.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Ordinary Shares · 10,000 shares

Expires 2030-06-07

F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year.

SEC source: 0001209191-20-035144 · doc4.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,240

Underlying: Common Stock · 10,240 shares

Expires 2030-06-03

F1 · derivative.exercise_date: The stock option vests in equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001493152-20-009770 · ownership.xml · derivative · entry 2

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,035

Underlying: Common Stock · 43,035 shares

Expires 2030-05-20

F2 · derivative.exercise_date: All of the stock options will vest on November 20, 2020.

SEC source: 0001493152-20-009770 · ownership.xml · nonDerivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,938

F1 · shares: All of the restricted stock will vest on November 20, 2020.

SEC source: 0001104659-20-013515 · a4.xml · nonDerivative · entry 2

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · kind: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), each outstanding restricted stock award held by reporting person was disposed of pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer.

SEC source: 0001104659-20-013515 · a4.xml · nonDerivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,259

F1 · kind: Represents shares tendered to the Denali Merger Sub, Inc. ("Purchaser") in connection with the closing on February 10, 2020 of a cash tender offer by Purchaser to acquire common stock of Issuer in exchange for $4.00 per share in cash, subject to any required withholding of taxes, without interest.

SEC source: 0001596771-19-000120 · primary_doc.xml · nonDerivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,537

F1 · kind: The sales reported in this Form 4 represent shares sold automatically to cover the tax liability incurred incident to the vesting of previously granted restricted stock.

F1 · shares: The sales reported in this Form 4 represent shares sold automatically to cover the tax liability incurred incident to the vesting of previously granted restricted stock.

SEC source: 0001209191-19-047836 · doc4.xml · derivative · entry 2

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,240

Underlying: Common Stock · 10,240 shares

Expires 2029-08-28

F2 · derivative.exercise_date: The stock option vests in equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001209191-19-047836 · doc4.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,475

Underlying: Common Stock · 20,475 shares

Expires 2029-08-28

F1 · derivative.exercise_date: The stock option vests in equal monthly installments over a three year period, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001209191-19-048210 · doc4a.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,475

Underlying: Common Stock · 20,475 shares

Expires 2029-08-28

F1 · derivative.exercise_date: The stock option vests in equal monthly installments over a three year period, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

F2 · balance_after: Due to administrative error, a separate option award was erroneously included on the original Form 4 filed on August 30, 2019. That original Form 4 is hereby amended in its entirety.